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ABSTRACT: Tenocytes serve to synthesize and maintain collagen fibrils and other extracellular matrix proteins in
tendon. Despite the high prevalence of tendon injury, the underlying biologic mechanisms of postnatal tendon
growth and repair are not well understood. IGF1 plays an important role in the growth and remodeling of numerous
tissues but less is known about IGF1 in tendon. We hypothesized that IGF1 signaling is required for proper tendon
growth in response tomechanical loading through regulation of collagen synthesis and cell proliferation. To test this
hypothesis, we conditionally deleted the IGF1 receptor (IGF1R) in scleraxis (Scx)-expressing tenocytes using a
tamoxifen-inducibleCre-recombinase systemandcaused tendongrowth inadultmiceviamechanical overloadof the
plantaris tendon.ComparedwithcontrolScx-expressing IGF1R-positive (Scx:IGF1R+)mice, inwhichIGF1Rispresent
in tenocytes, mice that lacked IGF1R in their tenocytes [Scx-expressing IGF1R-negative (Scx:IGF1RD) mice] demon-
strated reduced cell proliferation and smaller tendons in response tomechanical loading.Additionally,we identified
thatboth thePI3K/proteinkinaseBandERKpathwaysareactivateddownstreamofIGF1andinteract inacoordinated
manner to regulate cell proliferation and protein synthesis. These studies indicate that IGF1 signaling is required for
proper postnatal tendon growth and support the potential use of IGF1 in the treatment of tendon disorders.—Disser,
N. P., Sugg, K. B., Talarek, J. R., Sarver, D. C., Rourke, B. J., Mendias, C. L. Insulin-like growth factor 1 signaling in
tenocytes is required for adult tendon growth. FASEB J. 33, 12680–12695 (2019). www.fasebj.org
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Tendon is a dense connective tissue that serves to transmit
force from muscle to bone during mechanical loading. The
tendon extracellular matrix (ECM) is composed mostly of
type I collagen, as well as type III collagen, elastin, and
proteoglycans (1). Tendon fibroblasts, or tenocytes, are the
main cell type in tendon and are responsible for the syn-
thesis, organization, and maintenance of the ECM (2). In
response to high stress repetitive mechanical loading, such
as that which occurs during resistance exercise, tendons
adapt by undergoing hypertrophy (3). This results in an
increase in tendon cross-sectional area (CSA) through an
inductionof cellproliferationandcollagenproduction (4–6).
Repetitive loading can also induce a chronic inflammatory
condition referred to as tendinopathy (7, 8).Despite thehigh
prevalence of tendon injury and overall importance of ten-
don in maintaining musculoskeletal health, the underlying
biologicmechanisms that regulate postnatal tendongrowth
are not well understood. Further, as tendinopathy is
thought to arise due to improper responses to mechanical
stimuli,gainingagreaterunderstandingof thebasicbiologic
mechanisms of tendon growth could help in the develop-
mentofnewtherapies for the treatmentof tendondisorders.
IGF1, which can be induced by growth hormones and
other mechanical signals, is an integral component of the
growth and development of several different tissues (9).
IGF1 is typically bound to an IGFBP carrier protein, and
uponproteolyticdegradationof the IGFBP, IGF1 is liberated
andcan interactwith its receptor, IGF1R,which is amember
of the receptor tyrosine kinase (RTK) family of trans-
membrane receptors (10). IGF1 is a potent activator of
skeletal muscle cell proliferation and protein synthesis, and
the deletion of IGF1 in muscle fibers results in fiber atrophy
anddisruptedmetabolism(9, 11). Inbone,overexpressionof
IGF1 results in increased bone mineral density, and the
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inactivation of IGF1R in osteoblasts impairs matrix miner-
alization (12). However, the role of IGF1 in tendon growth
has not been fully examined. Previous studies in tendon
have revealed an increase in tendon collagen synthesis fol-
lowing IGF1 treatment in engineered tendon tissue and
healthy human tendon, as well as in horses with tendino-
pathies (13–15).Given the role that IGF1plays in the growth
of other tissues as well as observations of increased IGF1
expression correlated with enhanced ECM production in
tendons, we sought to determine the mechanisms behind
IGF1-mediated tendon growth.We hypothesized that IGF1
signaling is required for proper tendon growth in response
to mechanical loading through a coordinated induction of
collagen synthesis and cell proliferation. To test this hy-
pothesis, we induced tendon growth in adult mice via me-
chanical overloadof theplantaris tendonanddeleted IGF1R
in scleraxis (Scx)-expressing tenocytes. Additionally, we
performed a series of in vitro experiments in which we
treated tenocytes with IGF1 for various durations to exam-




All animal studies were approved by the University ofMichigan
and Hospital for Special Surgery Institutional Animal Care and
Use Committees. We used 3 strains of mice in this study.
Wild-type C57BL/6J (strain 000664) mice and IGF1Rflox mice
(strain 012251) in which exon 3 of IGF1R is flanked by loxP sites
(16)wereobtained fromThe JacksonLaboratory (BarHarbor,ME,
USA). ScxCreERT2 mice in which an IRES-CreERT2 sequence was
inserted between the stop codon and 39UTR in exon 2 of Scx (17)
were kindly provided by Dr. Ronen Schweitzer (Shriners Hospi-
tals for Children, Portland, OR, USA). Genotype of mice was de-
termined by PCR analysis of DNA obtained from a tail tendon
biopsy. After performing initial crosses between ScxCreERT2/CreERT2
and IGF1Rflox/flox mice, we generated ScxCreERT2/CreERT2:
IGF1Rflox/flox mice to allow us to inactivate IGF1R in Scx-
expressing cells upon treatment with tamoxifen [Scx-expressing
IGF1R-negative (Scx:IGF1RD) mice, in which IGF1R is absent in
tenocytes],whereasScx+/+:IGF1Rflox/floxmicewouldmaintain the
expression of IGF1R in Scx-expressing cells after tamoxifen
treatment [Scx-expressing IGF1R-positive (Scx:IGF1R+) mice,
in which IGF1R is present in tenocytes]. The age of mice in this
studywas;4mo. An overview of the alleles used in this study
is provided in Fig. 1A. Wild-type C57BL/6Jmice were used for
cell culture experiments, whereas Scx:IGF1R+ and Scx:IGF1RD
mice were used in whole animal studies.
Synergist ablation tendon growth procedure
Mice were treated daily with an intraperitoneal injection of
1 mg of tamoxifen (T5648; MilliporeSigma, Burlington, MA,
USA) dissolved in 50 ml of corn oil to activate CreERT2
recombinase in Scx-expressing cells. Tamoxifen treatment
began 3 d prior to surgery and continued on a daily basis until
tissue was harvested for analysis. Bilateral synergist ablation
procedures were performed under isoflurane anesthesia, as
previously described (6, 18). An overview of the time points
Figure 1. Experimental overview. A) Overview of the alleles used in this study, including the Scx wild-type (Scx+), Scx inducible Cre
(ScxCreERT2), IGF1R wild-type (IGF1R+), IGF1R floxed (IGF1Rflox), and IGF1R-null (IGF1RD) alleles. B) Timeline of tamoxifen
treatment, surgical overload, and tissue harvest. Tamoxifen was delivered on a daily basis beginning 3 d prior to surgery and
continued through tissue harvest. C) Overview of surgical overload procedure, in which the Achilles tendon is removed from the
animal, resulting in compensatory hypertrophy of the synergist plantaris muscle and tendon. A neotendon area of new tendon
matrix forms around the original tendon. D) Relative expression of IGF1R at 7 and 14 d, with the Scx:IGF1RD group normalized to
the Scx:IGF1R+ group at each time point. Values are means 6 CV. Differences for each time point tested with a Student’s t test: a,
significantly different (P , 0.05) from Scx:IGF1R+ group; n 5 4 animals/group.
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and surgical procedures are shown in Fig. 1B, C. The Achilles
tendon was surgically excised to prevent the gastrocnemius
and soleus muscles from plantarflexing the talocrural joint,
resulting in compensatory hypertrophy of the adjacent syn-
ergist plantaris muscle and tendon. A small incision was
created in the skin above the posterior paw plantarflexor
tendons, and the Achilles tendon was isolated and excised,
leaving stumps at the myotendinous junction and calcaneus.
The skin was closed with GLUture (Zoetis, Parsippany, NJ,
USA), buprenorphine was administered for postoperative
analgesia, and ad libitum weight bearing and cage activity
were allowed in the postoperative period. Mice were closely
monitored during the postoperative period for any adverse
reactions. At tissue harvest, the left plantaris tendons were
divided into proximal and distal halves and snap frozen at
280°C for gene expression analysis, whereas the right plan-
taris tendons were used for histology. After the tendons were
removed, mice were euthanized by cervical dislocation.
Plantaris tendons from additional nonoverloaded Scx:IGF1R+
mice were obtained as previously described for gene expres-
sion analysis.
Histology
Histology was conducted as previously described (6, 18).
Plantaris tendons obtained from animals were immediately
placed in 30% sucrose solution for 1 h, snap frozen in
Tissue-Tek Optical Cutting Temperature (OCT) Compound
(SakuraFinetek, Torrance,CA,USA), and stored at280°Cuntil
use. Tendons were sectioned at a thickness of 10 mm in a
cryostat. Sections were stained with hematoxylin and eosin
to determine tendon CSA and cell density. To evaluate
proliferating cells, tendon sections were fixed in 4% para-
formaldehyde, permeabilized with 0.2% Triton X-100, blocked
with 5% goat serum, and incubated with rabbit anti-Ki67 an-
tibodies (1:100, ab16667; Abcam,Cambridge, MA, USA) and
goat anti-rabbit antibodies conjugated to AF555 (1:300,
A-21429; Thermo Fisher Scientific, Waltham, MA, USA), as
well as wheat germ agglutinin lectin conjugated to Alexa Fluor
488 (AF488) (1:200, W11261; Thermo Fisher Scientific) to
identify the ECM, and DAPI (1:500; MilliporeSigma) to label
nuclei. Slides were imaged using a BX-51 microscope and
camera (Olympus, Tokyo, Japan) for the hematoxylin and eosin
slides,whereas anA1 confocal lasermicroscope (Nikon, Tokyo,
Japan) was used for the Ki67 slides. Quantification of tendon
size and cell density was performed using ImageJ [National
Institutes of Health (NIH), Bethesda, MD, USA].
Cell isolation
Tenocytes were isolated from the tail tendons of mice as pre-
viously described (18, 19). Mice were deeply anesthetized with
isoflurane, the tail was removed, and animals were euthanized
by cervical dislocation. Fascicles of tail tendons were isolated,
finelyminced, andplaced in low-glucoseDMEM(ThermoFisher
Scientific) containing 0.2% type II collagenase (Thermo Fisher
Scientific) for 1 h at 37°C with constant agitation. An equal vol-
ume of growth medium (GM), which contains low-glucose
DMEM with 10% fetal bovine serum (Thermo Fisher Scientific)
and 1% antibiotic antimycotic (AbAm; Thermo Fisher Scientific),
was added to the digested tissue to inactivate the collagenase.
Tenocytes were pelleted by centrifugation at 2500 g for 10 min,
resuspended inGMandplated.Alldishesor chamber slidesused
in the studywere coatedwith type I collagen (Corning, Corning,
NY, USA). Cells were maintained in humidified incubators
at 37°C and 5% CO2. Passage 2–4 tenocytes were used in
experiments.
In vitro IGF1 cell culture time course
Tenocyteswere grown to 60% confluence inGMand switched
to medium containing DMEMwith 2% horse serum (Thermo
Fisher Scientific) and 1% AbAm (Thermo Fisher Scientific),
referred to as differentiation medium (DM) overnight. The
next day, medium was replaced with DM containing
100 ng/ml of IGF1 (R&DSystems,Minneapolis,MN,USA) for
a period of time ranging from 1, 2, 6, or 24 h. Cells that un-
derwent the same procedure but did not receive IGF1 treat-
ment are referred to as 0 h cells. At the end of the treatment
period, RNA was isolated as described in RNA sequencing
and gene expression.
In vitro signal transduction assays
Tenocytes were grown to 90% confluence in GM and serum
starved inDMEMwith 1%AbAm for 3 h, followed by treatment
with either the MEK1/2 inhibitor PD98059 (50 mM; InvivoGen,
San Diego, CA, USA) to block ERK1/2 activation or the PI3K
inhibitor wortmannin (10 mM; InvivoGen) to inhibit protein ki-
nase B (Akt) activation for 1 h. Cells were then treated with
100ng/ml IGF1 for 5, 15, 30, or 60min, scraped from their dishes,
and homogenized in RIPA buffer (Thermo Fisher Scientific)
containing 1% protease and phosphatase inhibitors (Thermo
Fisher Scientific).
In vitro proliferation
Cell proliferation as measured by the uptake of bromodeoxy-
uridine (BrdU) was measured as previously described by
Sugg et al. (18). Tenocytes at 50% confluence were incu-
bated overnight in DM and then treated with DM containing
100 ng/ml of IGF1 (R&D Systems), PD98059 (50 mM; Invi-
voGen), or wortmannin (10 mM; InvivoGen). Following a 16-
h overnight incubation, fresh mediumwas added along with
20 mMof BrdU (MilliporeSigma) for 1 h. After treatment with
BrdU, cells were fixed in ice-cold methanol, permeabilized
with 0.5%TritonX-100, and the BrdUepitopewas exposed by
denaturing DNA with 2 M HCl. Cells were then incubated
with anti-BrdU antibodies (1:50, G3G4; Developmental
Studies Hybridoma Bank, Iowa City, IA, USA), and second-
ary antibodies were conjugated to AF555 (1:200, A-21127;
Thermo Fisher Scientific) and DAPI (1:500) to identify nuclei.
The number of BrdU+ nuclei as a fraction of total nuclei was
quantified in 5 randomly selected fields of a single experi-
ment from 4 independent experiments performed per group.
Plates were imaged in an Evos FLmicroscope (Thermo Fisher
Scientific) and quantified with ImageJ software.
In vitro surface sensing of translation labeling
Protein synthesis in cultured tenocytes was measured using a
surface sensing of translation (SUnSET) technique, as modi-
fied fromstudies inC2C12myoblast cells (20). Tenocyteswere
grown to 90% confluence in GM and serum starved in DMEM
with 1% AbAm for 3 h, followed by treatment with either
PD98059, wortmannin, or the protein synthesis inhibitor cy-
cloheximide (R&DSystems) for 1 h. Cellswere then treated for
30 min with 0.25 mM puromycin (MilliporeSigma), which is a
tyrosyl-tRNA analog that is incorporated into newly trans-
lated proteins (21), followed by 100 ng/ml of IGF1 for 1 h. At
the end of the treatment period, tenocytes were scraped from
their dishes and homogenized in RIPA buffer (Thermo Fisher
Scientific) containing 1% protease and phosphatase inhibitors
(Thermo Fisher Scientific).
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In vitro procollagen I labeling
To label procollagen I in proliferating or nonproliferating cells,
tenocytes were cultured as described above, incubated with DM
overnight, and then treated with either normal DM or DM con-
taining 100 ng/ml of IGF1. The thymidine analog EdUwas used
in lieu of BrdU because the acid denaturing step required for
BrdU detection degraded procollagen I epitopes. Following a
24-h incubation, fresh medium was added along with 10 mM of
EdU (Thermo Fisher Scientific) for 1 h. Cells were fixed in 4%
paraformaldehyde, permeabilized with 0.5% Triton X-100, and
EdUwas detected using a Click-iT kit (Thermo Fisher Scientific).
Cells were then incubated with antibodies against procollagen I
(1:100, sc-30136; SantaCruzBiotechnology,Dallas, TX,USA) and
b-tubulin (1:200, ab6161; Abcam) and secondary antibodies
conjugated to AF488 or AF647 (1:300, A11006 and A32733;
ThermoFisher Scientific). Slideswere imaged inanLSM880 laser
scanning confocal microscope (Carl Zeiss GmbH, Oberkochen,
Germany).
RNA sequencing and gene expression
RNA was isolated from tendons and cultured tenocytes as pre-
viously described (18, 22). Plantaris tendons or tenocytes were
homogenized in Qiazol (Qiagen, Germantown, MD, USA), and
RNA was purified with an miRNeasy Micro Kit (Qiagen) sup-
plemented with DNase I (Qiagen). RNA concentration and
qualitywere determinedusing aNanoDrop2000 (ThermoFisher
Scientific) and a TapeStation 2200 (Agilent Technologies, Santa
Clara, CA, USA).
ForRNAsequencing (RNAseq), 250ng (forwhole tendons) or
500 ng (for culture cells) was delivered to the University of
Michigan Sequencing Core for analysis. Sample concentrations
were normalized and cDNApoolswere created for each sample,
and then they were subsequently tagged with a barcoded oligo
adapter to allow for sample-specific resolution. Sequencing was
carried out using an IlluminaHiSeq 2500 platform (Illumina, San
Diego, CA,USA)with 50 bp single end reads. RawRNAseq data
were quality checked using FastQC v.0.10.0 (Babraham Bio-
informatics, Cambridge, United Kingdom). Alignment to the
reference genome (mmu10; University of California, Santa Cruz,
Santa Cruz, CA, USA), differential expression based on counts
per million mapped reads, and postanalysis diagnostics were
carried out using edgeR (23). A Benjamini-Hochberg false dis-
covery rate procedure was applied to correct P values for mul-
tiple observations, and these false discovery rate–corrected P
values are reported as q values. Sequencing data have been de-
posited to the NIH Gene Expression Omnibus (GSE131804;
https://www.ncbi.nlm.nih.gov/geo/).
For quantitative PCR (qPCR), using iScript Reverse Tran-
scription reagents (Bio-Rad, Hercules, CA, USA), RNA was re-
verse transcribed into cDNA that was amplified in a CFX96
real-time thermal cycler (Bio-Rad) using iTaq Universal SYBR
Green Supermix (Bio-Rad). Target gene expression was nor-
malized to the stable housekeeping gene cyclophilin D (Ppid)
using the 2-DCt method. Cyclophilin D was selected as a house-
keeping gene from RNAseq data and validated with qPCR. For
cell culture experiments, relative copy number was calculated
using the linear regression of efficiency method (24). Primer se-
quences are provided in Supplemental Data S1.
Biologic pathway analysis
Expression data from RNAseq measurements were imported
into Ingenuity Pathway Analysis software (Qiagen) to assist in
predicting cellular and molecular pathways and processes that
were altered in response to manipulating IGF1 signaling in
tendons.
Western blots
Western blots were performed as previously described (18, 25).
Tendons and cell pellets were homogenized in ice-cold RIPA
buffer (ThermoFisher Scientific) supplementedwith 1%protease
and phosphatase inhibitor cocktail (Thermo Fisher Scientific). A
BCA assay (Thermo Fisher Scientific) was used to determine
protein concentration. Protein homogenates were diluted in
Laemmli’s sample buffer, placed in boiling water for 2 min, and
20mgofproteinwas separatedon either 6 or 12%SDS-PAGEgels
depending on the protein of interest. Proteins were transferred
to nitrocellulose or PVDF membranes (Bio-Rad) using the
Trans-Blot SD semidry transfer apparatus (Bio-Rad), blocked
with 5% nonfat powderedmilk in TTBS solution, and incubated
with primary antibodies (1:1000; Cell Signaling Technology,
Danvers, MA, USA) against phosphorylated (p)-IGF1RbY1135
(3918), IGF1Rb (3025), p-IRS1S612 (2386), IRS1 (2382), p-AktT308
(13038), p-AktS473 (4060), Akt (4691), p-p70S6 kinase (p70S6K)
T389 (9234), p-p70S6KT421/S424 (9204), p70S6K (2708), p-ERK1/2T202/
Y204 (4370), ERK1/2 (4695); or primary antibodies from Santa
Cruz Biotechnology (1:1000) against procollagen type I
(sc-30136); or primary antibodies from Abcam (1:1000) against
b-tubulin (ab6046), p-ELKS383 (ab34270), or ELK (ab32106); or
primary antibodies from MilliporeSigma against pIRS1Y608
(1:1000) or puromycin (1:2000; 12D10). Following primary an-
tibody incubation,membraneswere rinsed and incubatedwith
HRP-conjugated secondary antibodies (1:10,000; from either
Abcam or Cell Signaling Technology). Proteins were detected
using Clarity enhanced chemiluminescent reagents (Bio-Rad)
and visualized using a digital chemiluminescent documenta-
tion system (Bio-Rad). Coomassie staining of membranes was
performed to verify equal protein loading.
Statistics
Results are presented as means 6 SD or means 6 coefficient of
variation (CV). Prism v.8.0 (GraphPad Software, La Jolla, CA,
USA) was used to conduct statistical analyses for all data except
RNAseq. A 2-way ANOVA followed by Fisher’s post hoc sorting
(a = 0.05) evaluated the interaction between time after synergist
ablation and IGF1R knockdown. For cell culture experiments,
differences between groups were tested with an unpaired Stu-
dent’s t test (a = 0.05) or a 1-way ANOVA followed by Fisher’s
post hoc sorting (a = 0.05).
RESULTS
To study the role of IGF1 signaling in adult tendon hy-
pertrophy, we treated mice with tamoxifen, induced a
mechanical overload in plantaris tendons of Scx:IGF1R+
and Scx:IGF1RD mice, and analyzed tendons at either 7 or
14 d after creation of the growth stimulus (Fig. 1A–C).
Tamoxifen treatment resulted in an over 90% reduction in
IGF1R expression in Scx:IGF1RDmice comparedwith Scx:
IGF1R+miceat both7and14d (Fig. 1D).We thenanalyzed
histologic changes in plantaris tendons. As previously
observed in other models of synergist ablation-mediated
mechanical overload, a neotendon tissue formed laterally
around the original tendon toward the direction of the
removed Achilles tendon (Fig. 2A–D). The neotendon
matured and filled in with collagen over time; however,
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growth was blunted in the Scx:IGF1RD mice (Fig. 2A–D).
The total tendonCSAwas not different between groups at
7d, but by 14d the totalCSAofScx:IGF1R+micewas twice
as large asScx:IGF1RDmice (Fig. 2D). This occurred due to
a greater expansion of the neotendon of Scx:IGF1R+ mice
over time, whereas Scx:IGF1RD mice displayed no change
between 7 and 14d (Fig. 2C). No differences in cell density
were observed in the original tendon, neotendon, or total
tendon across time or genotype (Fig. 2E–G); however, the
percentage of proliferating cells was 2-fold greater in the
neotendonofScx:IGF1R+mice comparedwithScx:IGF1RD
mice (Fig. 2H–J).
Wethensought to identify changes in the transcriptome
of plantaris tendons of Scx:IGF1R+ mice and Scx:IGF1RD
mice in response to mechanical overload using RNAseq.
At 7 d, there were 1108 transcripts that were at least 50%
differentially regulatedbetweengenotypes, but therewere
only 159 transcripts at 14 d (Fig. 3A, B). Pathway enrich-
ment analysis was performed to evaluate cellular func-
tions, and signaling pathways predicted to be different
between groups over time. Several of the pathways iden-
tified were involved with growth and differentiation, cy-
toskeletal signaling, and ECM production (Table 1). We
selected several genes related to these processes to further
explore and report in Fig. 3C–E, and we also performed
qPCRvalidationof a subset of relevant genes (Table2).All
gene names have been listed in Table 3. Compared to
nonoverloaded controls, several growth factors and sig-
naling molecules including Adam12, Bmp1, Ctsd, Igf1, and
Pappa were up-regulated in all overloaded groups,
whereas Bmp6, Fgf2, Inhbb, and Vegfa were down-
regulated at all time points (Fig. 3C). There was also an
up-regulation in Bmp1, Bmp6, Igf1, Inhba, Pdgfa, Pdgfb,
Tgfb1, Tgfb2, Wnt5b, and Wnt9a in 7 d Scx:IGF1RD mice
compared with 7 d Scx:IGF1R+ mice, and by 14 d Fgf2
and Tgfb2 were significantly higher in Scx:IGF1RD mice
(Fig. 3C). For genes involved in the liberation of IGF1
from IGFBPs,C1s2was up-regulated at 7 d andCtsdwas
up-regulated at 14 d in Scx:IGF1RD mice, whereas no
differences in Pappa were observed between genotypes
(Fig. 3C). With regards to cell proliferation, and tenocyte
specification and differentiation, Acta2, Ccna2, Ccnb1,
Ccne1, Cdk1, Cdk2, Cdk4, Cdk6, Cfi1, Itgav, Mki67, Pcna,
Ptk2, Snai1, Trp53, and Vim were up-regulated in all
overloaded groups (Fig. 3D).Cdkn1b, Itgb3, Rerg, S100a4,
Scx, Snai1, and Yap1 were up-regulated in 7-d Scx:
IGF1RD mice compared with 7-d Scx:IGF1R+ mice,
whereas Acta2, Cfl1, Itgav, Mcm6, and Pcna were
down-regulated (Fig. 3D). At 14 d, Rerg and Scx were
up-regulated in Scx:IGF1RD mice (Fig. 3D). For ECM
genes, Bgn, Co1a1, Co1a2, Col3a1, Col5a1, Col6a1, Col14a1,
Fn1, Mmp2, Mmp3, Mmp14, Postn, Smoc2, Timp1, Tnc,
Vcan, and Wisp1 were up-regulated in overloaded
groups, whereas Compwas down-regulated (Fig. 3E). In
Scx:IGF1RD mice, Bgn, Col1a1, Col1a2, Col3a1, Col5a1,
Comp, Fn1, Mmp2, and Mmp14 were up-regulated at
7 d andCol5a1 at 14d,whereasMgpwasdown-regulated
at 7 and 14 d compared with Scx:IGF1R+ mice (Fig. 3E).
Based on the in vivo results that suggested a role for
IGF1 in controlling cell cycle behavior and ECM synthesis
involving PI3K/Akt and ERK signaling, we took a
reductionist approach to evaluate IGF1 signaling in vitro
using cultured primary tenocytes. We observed that IGF1
treatment resulted in IGF1RY1135phosphorylation, leading
to earlydownstreamactivationof IRS1Y608, ERK1/2T202/Y204,
AktT308, AktS473, p70S6KT389, and p70S6KT421/S424 (Fig.
4A). Whereas ERK1/2T202/Y204, AktT308, and AktS473
phosphorylation decreased following 5 min of IGF1
treatment, p70S6KT389 and p70S6KT421/S424 activation
was sustained from 15 through 60 min after treatment,
and phosphorylation of ELK1S383 was detected at 30 and
60 min (Fig. 4A). Phosphorylation of the inhibitory
IRS1S612 site was detected at 30 and 60 min following
IGF1 treatment (Fig. 4A).
To further explore the effect of IGF1 treatment on
tenocytes, we performed RNAseq using cultured teno-
cytes thatwere not treatedwith IGF1, or treatedwith IGF1
for 1, 2, 6, or 24 h. At 1 h, over 400 transcripts were at least
50% differentially regulated and q , 0.05, whereas over
1000geneswere similarlyaffectedat 2,6, and24h (Fig. 4B).
We used the same panel of genes explored in whole ten-
dons for further analysis in cultured tenocytes. Across
these transcripts, Egf, Mmp2, Tnmd, Trp53, Vim, and Yap1
were not affected by IGF1 treatment (Fig. 4C–E). For the
growth factors and signaling molecules that were differ-
entially regulated inwhole tendonsofScx:IGF1R+ andScx:
IGF1RD mice, there was an induction of Fgf2, Pdgfa, Pdgfb,
Tgfb1, andWnt9aby2h,whereas Igf1wasdown-regulated
compared with untreated cells (Fig. 4C). By 24 h, with the
exception of Bmp1 and Tgfb2, nearly all other growth fac-
tors and signaling molecules that were differentially reg-
ulated in tendons were down-regulated in cultured
tenocytes (Fig. 4C). Cfl1, Itgb3, Pcna, Scx, and Snai1
demonstrated an early up-regulation in response to IGF1
treatment, whereas Acta2 and Cdkn1b were initially
reduced (Fig. 4D). By 24 h Mcm6, Pcna, and S100a4
were up-regulated and Acta2 was suppressed (Fig. 4D).
The ECM genes Mgp, Mmp3, Spp1, Timp1, and Tnc
were up-regulated by 2 h, whereas Bgn, Col1a1, Col1a2,
Ctgf, Cyr61, and Smoc2 were down-regulated (Fig. 4E).
At 24 h, Col3a1, Col5a1, Has2, Mgp, and Mmp14 were in-
duced, and Bgn and Comp were reduced in IGF1-treated
tenocytes.
As we observed differences in cell proliferation in
vivo and that IGF1 affected the expression of cell cycle
control genes in vitro, we next determined if IGF1 directly
impacts the proliferation of cultured tenocytes, and
the role of the PI3K/Akt and ERK pathways in this pro-
cess. We sought to validate the findings for Mki67 ex-
pression in RNAseq data, and using qPCRwe observed a
slight .1.5-fold transient induction at 2 h after IGF1
treatment, and a near 8-fold induction in Mki67 at 24 h
(Fig. 5A). In support of these findings, we observed a
2.5-fold increase in the number of BrdU+ tenocytes in
response to IGF1 treatment (Fig. 5B). Inhibiting the
PI3K/Akt pathway with wortmannin did not im-
pact IGF1-mediated tenocyte proliferation or Mki67
expression, whereas blocking ERK1/2T202/Y204 with
PD98059 reduced cell proliferation and Mki67 expression
(Fig. 5B, C).
Based on the differences in tendon size between Scx:
IGF1R+ andScx:IGF1RDmice, thedifferential expressionof
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Figure 2. Effect of IGF1R deletion on tendon growth and cell proliferation. A) Representative histology of cross-sections from Scx:
IGF1R+ and Scx:IGF1RD mice obtained at either 7 or 14 d after mechanical overload demonstrating general morphology, cell
density, and abundance of proliferating cells. The original tendon (OT) and neotendon (NT) are indicated by the hashed line.
ECM, green; nuclei, blue; Ki67 (proliferating cells), red. Scale bar for all sections is 200 mm. B–D) Area measurements of tendons,
with respect to the original tendon (B), neotendon (C), and total tendon (D). E–G) Cell density measurements of tendons, with
respect to the original tendon (E), neotendon (F), and total tendon (G). H–J ) Cell proliferation measurements, with respect to
the original tendon (H), neotendon (I), and total tendon (J ). Values are means 6 SD, with individual data points presented.
Differences tested with a 2-way ANOVA: significantly different (P , 0.05) from 7D Scx:IGF1R+ mice (a); significantly different
(P , 0.05) from 7D Scx:IGF1RD mice (b); and significantly different (P , 0.05) from 14D Scx:IGF1R+ mice (c); n $ 3 mice/group.
7D, 7 d; 14D 14 d.
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Col1a1 and Col1a2 in whole tendons, and the cell culture
RNAseq data, we sought to determine whether IGF1 di-
rectly induces type I collagen expression in tenocytes.
Using qPCR, there were no differences in Col1a1 and Co-
l1a2 expression following treatmentwith IGF1 (Fig. 6A,B).
Wealso did not observedose- or time-dependent effects of
Figure 3.Whole tendon RNAseq. A, B) Volcano plot demonstrating log2 fold change (FC) and q values of all measured transcripts
in plantaris tendons from Scx:IGF1R+ and Scx:IGF1RD mice at 7 (A) and 14 d (B) after surgical overload. Values .10 are shown
directly on the top or side border of the graph. Genes with a .1.5-fold up-regulation in Scx:IGF1RD mice (log2 fold change
.0.585) and q value , 0.05 (2log10 q . 1.301) are shown in red. Genes with a .1.5-fold down-regulation in Scx:IGF1R
D mice
(log2 fold change ,20.585) and q value , 0.05 (2log10 q . 1.301) are shown in blue. All other genes are shown in black. C–E)
Heat maps demonstrating the log2 fold change in selected genes from RNAseq that are growth factors, cytokines, or genes
involved with activating extracellular ligands (C); involved in cell proliferation and tenocyte specification and differentiation (D);
or components or regulators of the ECM (E). The fold change value is displayed for each group relative to nonoverloaded Scx:
IGF1R+ (control) mice. Differences between groups tested using edgeR: different (q , 0.05) in the respective overloaded group
to nonoverloaded Scx:IGF1R+ mice (a); different (q , 0.05) between 7D Scx:IGF1R+ and 7D Scx:IGF1RD mice (b); and different
(q , 0.05) between 14D Scx:IGF1R+ and 14D Scx:IGF1RD mice (c); n = 4 mice per group. 7D, 7 d; 14D, 14 d.
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IGF1 on type I collagen protein abundance in tenocytes,
although we did note that cells that are in the S phase, as
indicated by the presence of EdU+ nuclei, reduce type I
collagen production (Fig. 6C–E).
Finally, we sought to determine the effect of IGF1 sig-
naling on general protein synthesis. Using the Sunset
method in which the tyrosyl-tRNA analog puromycin is
incorporated into newly synthesized proteins, we treated
tenocytes with IGF1 and observed a 2-fold increase in
puromycin incorporation.Thebroad-spectrumtranslation
inhibitor cycloheximide as well as wortmannin blocked
IGF1-mediated protein synthesis in tenocytes, but sur-
prisingly ERK1/2 inhibition resulted in a nearly 6-fold
increase in protein synthesis (Fig. 7A, B). To investigate
this phenomenon in more detail, we probed for the
presence of permissive and inhibitory phosphoryla-
tion sites on components of the PI3K/Akt and ERK1/2
signaling pathways. As anticipated PD98059 blocked
ERK1/2T202/Y204 phosphorylation as well as phosphory-
lation of the downstream transcription factor ELK1S383,
and wortmannin inhibited AktT308 phosphorylation (Fig.
7C). However, inhibition of ERK1/2 surprisingly in-
creased AktT308 phosphorylation independent of IRS1Y608
phosphorylation, suggesting ERK1/2 is acting to inhibit
protein synthesis downstream of IRS1 (Fig. 7C). Further,
wortmannin decreased ERK1/2T202/Y204 and ELK1S383
phosphorylation and abolished phosphorylation of the
inhibitory IRS1S612 site, leading to increased phosphory-
lation of the permissive IRS1Y608 site (Fig. 7C). Based on
these findings, we propose a model in which IGF1 regu-
lates tenocyte proliferation and protein synthesis through
coordinated and intersecting actions of the PI3K/Akt and
ERK1/2 pathways (Fig. 8).
DISCUSSION
IGF1 is known to play a critical role in the growth and
adaptation of various musculoskeletal tissues (including
skeletal muscle, bone, and cartilage), but less is known
about tendon. To study tendon growth, we used the syn-
ergist ablation technique, in which the Achilles tendon is
surgically removed resulting in a supraphysiological
growth stimulus to the synergist plantaris tendon and
muscle (6, 22, 26–29). A neotendon matrix consisting of
immature collagen and other ECMproteins forms around
the plantaris tendon, and over a 1-mo period this ECM
matures and resembles the original tendon matrix (22).
















2.51E211 3.98E212 6.92E206 1.70E208 1.32E207 ND
Apoptosis 6.17E270 2.87E259 5.05E219 4.57E258 4.09E244 4.08E208
BMP signaling 1.55E204 7.59E203 2.19E202 7.94E203 8.71E204 ND
Chromosomal
replication
3.55E209 1.26E205 ND 6.92E204 3.63E202 ND
Cell cycle
regulation
2.82E204 3.02E203 ND 1.51E203 3.63E203 ND
Connective tissue
growth
1.70E234 8.73E228 3.16E209 5.45E228 6.74E222 2.01E206
EGF signaling 2.19E202 3.09E202 ND 4.07E202 ND ND
Ephrin A signaling 8.51E205 1.23E203 2.34E202 4.68E203 1.70E202 2.40E202
ERK/MAPK
signaling
1.12E205 2.09E204 9.12E203 9.55E203 1.82E203 ND
FAK signaling 8.91E206 6.03E204 8.51E203 3.63E202 ND ND
Fatty acid
b-oxidation
ND ND ND 1.66E202 2.09E202 ND
FGF signaling 7.94E204 2.63E204 6.92E203 2.40E203 9.33E203 ND
Inhibition of MMPs 7.24E206 1.35E205 2.51E202 1.62E208 3.16E211 6.92E204
Integrin signaling 1.00E211 8.13E210 2.51E203 8.91E206 1.26E204 ND
Organization of
ECM
1.82E226 1.75E227 3.00E216 9.47E229 8.64E229 3.37E211
p53 signaling 1.48E206 7.76E206 ND 5.89E205 8.13E205 ND
p70S6K signaling 3.72E204 4.37E203 ND 2.00E202 ND ND
PAK signaling 1.95E204 4.37E204 1.00E202 4.57E202 3.98E202 ND
PI3K signaling 2.40E206 4.90E204 ND 3.98E202 ND ND
Rac signaling 1.70E206 3.16E204 ND 1.51E202 4.79E202 ND
Signaling by Rho
GTPases
5.37E209 1.48E206 ND 2.24E204 8.51E203 ND
Sonic Hedgehog
signaling
8.51E203 2.34E203 ND 3.09E203 1.23E202 ND
TGF-b signaling 1.20E204 1.38E202 ND 6.92E203 3.24E203 ND
The P values of select affected or differentially regulated pathways or biologic functions that were identified using Ingenuity Pathway Analysis.
Ctrl, control; ND, not significantly different.
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The neotendon is enriched in a population of Scx-
expressing tenocytes that appear to arise from CD146+
progenitor cells in theperivascular regionof tendons (6, 22,
30). The increase in tenocytes in this model appears to
come about due to recruitment of CD146+ progenitor cells
into the tenogenic lineage and expansion of recruited
tenocytes prior to terminal differentiation (6, 22). By ap-
plying the synergist ablation model in a line of mice in
which IGF1R was deleted in tenocytes, we demonstrated
that IGF1 signaling is required for the proper growth of
tendons in adult animals. Compared with Scx:IGF1R+
mice, the plantaris tendons of Scx:IGF1RD mice had re-
duced CSAs and numbers of proliferating cells, and dis-
played alterations in growth factors, signaling molecules,
cell cycle control genes, and ECM components. Using in
vitro studies, we observed that IGF1 promotes a delayed
increase in cell proliferation and directs protein synthesis,
but surprisingly did not directly regulate type I collagen
expression. IGF1also induced the expressionofEgr1, Egr2,
and Scx, which are transcription factors that direct the
expression of genes that are important for tendon devel-
opment and growth (31, 32), as well as Snai1, which is
involved in fibroblast-mediated tissue growth (33). Fur-
thermore, we identified that both the PI3K/Akt and ERK
pathwaysareactivateddownstreamof IGF1andwork ina
coordinated manner to regulate cell proliferation and
protein synthesis. These results have important implica-
tions for our understanding of the basic biology of tendon
growth and may inform the treatment of tendinopathies.
Numerous growth factors have been studied in the
context of tenocyte proliferation in vitro. In the current
study, we observed a minor increase in markers of cell
proliferation within 2 h of IGF1 treatment but did not see
notable increases until 24 h. In mechanically stimulated
tendons, cell proliferation was reduced at 7 d in Scx:
IGF1RD mice. The CSA of tendons was similar between
mice at 7 d, but there was no appreciable growth in the
tendons of Scx:IGF1RD mice between 7 and 14 d, whereas
the tendons of Scx:IGF1R+ mice continued to grow there-
after. This suggests that IGF1 is regulating tenocyte
proliferation in an indirect manner, perhaps through
controlling the expression of other growth factors and
signaling molecules that directly regulate cell cycle
machinery. TGF-b1 signals through the TGF-bRII and
TGF-bRI receptors to activate the Smad2/3 and MAPK
signalingpathways in tenocytes (1), and treating tenocytes
with recombinant TGF-b1 increases tenocyte proliferation
(34, 35). PDGFa and PDGFb, which are activated by me-
chanical loading and signal through the PDGFRa and
PDGFRb receptors that are members of the RTK family,
also promote tenocyte proliferation and are required for
proper tendon growth (18, 36). Related to PDGFa and
PDGFb, FGF2 induces fibroblast growth and proliferation
also through RTK signaling, and in human renal fibro-
blasts, treatment with TGF-b1 increased cell proliferation
through inductionof FGF2 expression (37). In ourdata, the
expression of TGFb1, PDGFa, PDGFb, and FGF2 was
up-regulated by 2 h following IGF1 treatment in cultured
tenocytes, which corresponded tomodest increases in Fos,
Jun, Mki67, Pcna, cyclin E (Ccne1), Cdk2, and Cdk6, along
with a decrease in p27 (Cdkn1b). By 24 h, Bmp6 which
inhibits cell proliferation (38, 39) was down-regulated,
along with an up-regulation in Fos, Jun, Mki67, and
Pcna. Several cyclins (Ccna2, Ccnb1, and Ccne1) and
cyclin-dependent kinases (Cdk1, Cdk2, Cdk4, and Cdk6)
were alsoup-regulated, and adown-regulation in p27was
observed. At the whole tissue level, Bmp6 was elevated
and Pcna was decreased at d 7 in Scx:IGF1RD mice
TABLE 2. Gene expression data
Gene 7-d Scx:IGF1R+ 7-d Scx:IGF1RD 14-d Scx:IGF1R+ 14-d Scx:IGF1RD
CCNA2 8.19 6 1.90 4.48 6 0.66a 3.88 6 1.27a 4.38 6 0.97a
CCNB1 3.09 6 0.43 1.81 6 0.18a 1.19 6 0.60a 1.43 6 0.36a
CCND1 3.82 6 1.40 3.40 6 0.64 3.00 6 0.92 3.36 6 0.53
CCNE1 0.29 6 0.04 0.23 6 0.15 0.19 6 0.02 0.11 6 0.03a
CDKN1A 2.07 6 0.39 3.04 6 0.85a 2.23 6 0.46b 1.74 6 0.34b
COL1A1 224 6 72.4 372 6 46.7a 482 6 133a 561 6 74.5a,b
COL1A2 889 6 316 1450 6 159a 1890 6 551a 2270 6 61.4a,b
COL3A1 1308 6 346 1490 6 324 2070 6 640a 2250 6 472a,b
COL4A1 28.8 6 3.93 35.2 6 7.87 42.4 6 11.1a 46.5 6 8.06a,b
COL5A1 4.66 6 1.47 6.56 6 0.84 7.60 6 1.13a,c 9.47 6 1.42a,b
COL6A1 14.2 6 3.53 32.0 6 4.57a 34.1 6 11.8a 35.3 6 5.81a
EGR1 2.36 6 0.97 1.75 6 0.88 1.16 6 0.50a 0.93 6 0.45a
EGR2 0.17 6 0.04 0.15 6 0.07 0.10 6 0.05a 0.05 6 0.01a,b
HAS2 2.19 6 0.34 0.79 6 0.11a 1.20 6 0.42a 0.93 6 0.23a
MKI67 1.19 6 0.15 1.62 6 0.26 0.82 6 0.36a,b 1.03 6 0.36a,b
MKX 0.47 6 0.12 0.52 6 0.13 0.68 6 0.09a 0.78 6 0.14a,b
MMP2 5.37 6 1.11 7.95 6 1.53a 11.2 6 2.17a,b 11.4 6 1.57a,b
MMP14 3.24 6 0.63 5.12 6 0.44a 5.36 6 0.89a 4.51 6 0.69a
PCNA 22.2 6 4.63 14.3 6 3.84a 11.9 6 1.48a 13.8 6 2.61a
SCX 9.97 6 2.25 98.9 6 15.6a 19.3 6 7.62c 265 6 107a,b
TNMD 30.0 6 12.9 36.0 6 3.98 191 6 80.0a,b 150 6 37.5a,b
Expression of genes as measured by qPCR. Values are means 6 SD. Differences tested with a 2-way
ANOVA (a = 0.05): adifferent (P , 0.05) from 7-d Scx:IGF1+; bdifferent (P , 0.05) from 7-d Scx:IGF1D;
cdifferent (P , 0.05) from 14-d Scx:IGF1+.
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compared with Scx:IGF1R+ mice, and several other
growth factors andsignalingmoleculeswithdirect roles in
regulating cell proliferation were also differentially regu-
lated. Therefore, it is likely that IGF1 chiefly acts in an
indirectmanner to regulate tenocyte proliferation through
the regulation of other growth factors that act locally. The
delayed effect of IGF1 on inducing tenocyte proliferation
may explain why the neotendon areas were not different
between Scx:IGF1R+ and Scx:IGF1RD mice at d 7, but
at d 14 the neotendon of the Scx:IGF1R+ mice was 2-fold
larger thanScx:IGF1RDmice. Theremayalsobe an effect of
IGF1 on recruitment of progenitor cells into the tenogenic
lineage; however, we suspect that once progenitor cells
express Scx they are likely committed to tenogenesis.
Additionally, IGF1 is known to have an antiapoptotic role
in numerous cell types (40), which might explain why al-
tered cell proliferation at d 7 does not translate to differ-
ential cell density at d 14.
In addition to reducing cell proliferation, the loss of
IGF1R in tenocytes resulted in smaller tendons of
mechanically loadedmice. Because type I collagen is the
major constituent of the tendon ECM, and previous
studies have demonstrated that direct injection of IGF1
into tendons increases collagen synthesis (41), and pa-
tientswith acromegaly that have elevated levels of IGF1
also demonstrate an up-regulation of Col1a1 in their
tendons (42), we sought to determine whether IGF1
could directly regulate collagen synthesis in tenocytes.
Based on these studies, we anticipated that IGF1 would
directly induce type I collagen expression and that Scx:
IGF1RD mice would have reduced expression in their
tendons in response to mechanical overload. However,
Col1a1 and Col1a2, as well as Col3a1 and Col5a1, were
up-regulated in Scx:IGF1RD mice compared with Scx:
IGF1R+ mice, and treatment of tenocytes with IGF1 did
not induce Col1a1 or Col1a2 expression and resulted in
no change in type I procollagen protein abundance.
These results indicate that IGF1 does not directly induce
type I collagen gene expression, nor does it increase
type I collagen translation. In support of our observa-
tions of a delayed growth defect in tendons of Scx:
IGF1RD mice, 3-dimensional tissue engineered tendon
constructs treated with IGF1 demonstrated increased
size and hydroxyproline content, but this increase was
not observed until at least 2 wk after beginning treat-
mentwith IGF1 (15).Numerous other genes that encode
TABLE 3. List of gene names
Gene abbreviation Gene name Gene abbreviation Gene name
Acta2 Actin a 2 Itgb3 Integrin subunit b 3
Adam12 ADAM metallopeptidase domain 12 Mcm6 Minichromosome maintenance complex
component 6Bgn Biglycan
Mgp Matrix Gla proteinBmp1 Bone morphogenetic protein 1
Mki67 Marker of proliferation Ki-67Bmp6 Bone morphogenetic protein 6
Mmp2 Matrix metallopeptidase 2C1s2 Complement C1 2
Mmp3 Matrix metallopeptidase 3Ccna2 Cyclin A2
Mmp14 Matrix metallopeptidase 14Ccnb1 Cyclin B1
Pappa IGF-dependent IGFBP-4 proteaseCcne1 Cyclin E1
Pcna Proliferating cell nuclear antigenCdk1 Cyclin dependent kinase 1
Pdgfa Platelet derived growth factor subunit ACdk2 Cyclin dependent kinase 2
Pdgfb Platelet derived growth factor subunit BCdk4 Cyclin dependent kinase 4
Pdgfra Platelet derived growth factor receptor aCdk6 Cyclin dependent kinase 6
Pdgfrb Platelet derived growth factor receptor bCdkn1b Cyclin dependent kinase inhibitor 1B
Postn PeriostinCfi1 Cell division cycle 14A
Ptk2 Protein tyrosine kinase 2Col1a1 Collagen type I a 1 chain
Rerg RAS like estrogen regulated growth inhibitorCol1a2 Collagen type I a 2 chain
S100a4 S100 calcium binding protein A4Col4a1 Collagen type IV a 1 chain
Smoc2 Secreted modular calcium-binding protein 2Col3a1 Collagen Type III a 1 chain
Snai1 Snail family transcriptional repressor 1Col5a1 Collagen type V a 1 chain
Spp1 OsteopontinCol6a1 Collagen type VI a 1 chain
Tgfb1 Transforming growth factor b 1Col14a1 Collagen type XIV a 1 chain
Tgfb2 Transforming growth factor b 2Comp Cartilage oligomeric matrix protein
Timp1 Tissue inhibitor of metalloproteinases 1Ctgf Connective tissue growth factor
Tnc Tenascin CCtsd Cathepsin D
Trp53 Tumor protein P53Cyr61 Cellular communication network factor 1
Vcan VersicanEgf Epidermal growth factor
Vegfa Vascular endothelial growth factor AEgr1 Early growth response 1
Vim VimentinEgf2 Epidermal growth factor 2
Wisp1 Cellular communication network factor 4Fgf2 Fibroblast growth factor 2
Wnt5b Wnt family member 5BFn1 Fibronectin 1
Wnt9a Wnt family member 9AHas2 Hyaluronan synthase 2
Thbs4 Thrombospondin 4Igf1 Insulin-like growth factor 1
Tnc Tenascin CIgf1r Insulin-like growth factor receptor 1
Tnmd TenomodulinInhbb Inhibin subunit b B
Yap1 Yes associated protein 1Itgav Integrin subunit a V
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Figure 4. Signaling protein activation and RNAseq in cultured tenocytes treated with IGF1. A) Representative Western blots for
p-IGF1RY1135, total IGF1R, IRS1Y608, IRS1S612, total IRS1, p-ERK1/2T202/Y204, total ERK1/2, p-ELKS383, total ELK, p-AktT308, p-
AktS473, total Akt, p-p70S6KT389, p-p70S6KT421/S424, and total p70S6K in cultured tenocytes that were untreated (0 min) or treated
with IGF1 for 5, 15, 30, or 60 min. B–E) RNAseq analysis of untreated tenocytes (0 h) or tenocytes treated with IGF1 for 1, 2, 6, or
24 h. The fold change (FC) value displayed for each group is relative to tenocytes that were not treated with IGF1 (0 h). B)
(continued on next page)
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minor but important proteins that constitute or modify
the ECM such as Ctgf, Fn, Mmp2, Mmp3, Mmp14, Postn,
Smoc2, Spp1, Thbs4, Timp1, Tnc, Tnmd, Vcan, andWisp1
were induced by mechanical loading of tendons, and
Ctgf, Cyr61, Has2, Postn, Spp1, Thbs4, Timp1, Tnc, and
Vcan appeared to be directly or indirectly regulated by
IGF1 in cultured tenocytes. Although type I collagen is
the major protein in tendon ECM, mature collagen rich
matrices require the presence of proteoglycans and
matricellular proteins for proper construction and as-
sembly (43), and this may explain differences in CSA
observed at d 14.
To further explore the difference in size between
tendons of Scx:IGF1R+ and Scx:IGF1RD mice, we deter-
mined whether IGF1 regulated general protein synthe-
sis. IGF1 is known to activate the PI3K/Akt pathway,
which increases protein synthesis in skeletal muscle (1),
and local IGF1 can increase the protein fractional syn-
thesis rate in tendons of elderly men and patients with
Ehlers-Danlos syndrome (13, 44). Using the SUnSET
technique (20, 21), we observed that treating tenocytes
with IGF1 doubled protein synthesis rates, and blocking
Akt phosphorylation returned protein synthesis levels to
baseline. Based on these findings andour observations of
IGF1 and type I collagen synthesis, we propose that the
larger tendons in the Scx:IGF1R+ mice occurred in part
due to an increase in overall protein synthesis compared
with Scx:IGF1RD mice, rather than a direct increase
in collagen production. There are also other signaling
molecules regulated by IGF1 or mechano-sensing path-
ways in whole tissue that influence collagen production.
Further, the regulation ofCol1a1 andCol1a2 translation is
a complex process. Although translation requires that
active ribosomes bind to Col1a1 and Col1a2 mRNAs,
translation initiation also requires the interaction of
regulatory cofactors with the 59 stem loop and 39UTR of
the transcripts and the binding of these transcripts to
nonmuscle myosin and association with vimentin fila-
ments (45). Combined, our results indicate that IGF1
signaling contributes to protein synthesis in tenocytes
through an Akt-dependent mechanism, but IGF1 does
not appear sufficient to induce type I collagen translation
and likely works in a coordinated fashion with other
signaling pathways to regulate this process.
ERK is a well-known signaling pathway that is acti-
vated in response to mechanical loading, often through
the integrin aV/b3/FAK pathway (46). In whole ten-
dons, integrin aV (Itgav) and b3 (Itgab3) were induced in
response to synergist ablation, and RNAseq pathway
enrichment analysis predicted activation of integrin,
FAK, and ERK pathways, with a differential response
between Scx:IGF1R+ and Scx:IGF1RDmice. IGF1 is known
towork in coordination with integrin aV/b3/FAK signal
transduction, with ERK as a common and important
downstream effector kinase for both pathways (47). Al-
though mechanical loading is known to increase both
ERK and PI3K/Akt activation in tendons (18, 48–50), the
role of IGF1 in modulating ERK and PI3K/Akt in ten-
dons was not known. In this study, we observed that
IGF1 activates both ERK and PI3K pathways in teno-
cytes, and that ERK activation is required for the
IGF1-mediated increase in tenocyte proliferation. ELK1
is a transcription factor downstream of ERK that directs
the expression of genes involved in cell proliferation,
such as Fos and Jun that subsequently regulate expres-
sion of cyclins and cyclin-dependent kinases that control
cell cycle progression (51–54). ELK1S383 was phosphor-
ylated in response to IGF1 treatment, and as expected
this process was blocked by inhibiting ERKT202/Y204
phosphorylation. We also observed that ELK1S383 phos-
phorylation was inhibited by blocking PI3K. In other cell
types, the PI3K pathway can amplify ERKT202/Y204 phos-
phorylation through activating theMAP3KRAF (55), and
based on our results, there is likely a similar mechanism
occurring in tenocytes.
In addition to promoting cell proliferation, IGF1 also
increased protein synthesis by;2-fold in tenocytes, and
this process was dependent upon PI3K/Akt activation.
However, inhibiting ERKT202/Y204 phosphorylation resul-
ted in a nearly 6-fold induction in protein synthesis,
which was also a phenomenon that was not anticipated
because ERK activation is often associated with mild
increases in protein synthesis. This led us to look at po-
tential interactions between the PI3K/Akt and ERK
pathways. IGF1R phosphorylates IRS1Y608, which is the
principal site of interaction between IRS1 and the SH2
domain of PI3K. This causes the localization of PI3K
to the plasma membrane where it can catalyze the
conversion of PIP2 into PIP3 (56). Akt then binds
membrane-bound PIP3 through an N-terminal pleck-
strin homology domain, and it is activated by PDK1. The
recruitment of Akt to the membrane and the phosphor-
ylation of AktT308 through PDK1 allows Akt to be re-
leased into cytosol to activate mTOR, p70S6K, and other
downstream effectors (56). IRS1 can also be phosphory-
lated at S612, which blocks phosphorylation of its own
Y608 residue, and therefore IRS1S612 phosphorylation
inhibits the ability of IRS1 to activate PI3K (57). In some
cell types, p-ERKT202/Y204 can phosphorylate IRS1S612
(57, 58); however, we did not observe this response in
tenocytes. Instead, p-ERKT202/Y204 appears to modulate
protein synthesis downstream of IRS1 by inhibiting
phosphorylation ofAktT308 either directly or by targeting
a process downstream of IRS1Y608. This inhibitory role of
Number of genes that were significantly up-regulated (red) with a .1.5-fold up-regulation and q , 0.05, and significantly down-
regulated (blue) with a .1.5-fold up-regulation and q , 0.05. C–E) Heat maps demonstrating the log2 fold change in selected
genes from RNAseq that are growth factors, cytokines, or genes involved with activating extracellular ligands (C); involved in cell
proliferation and tenocyte specification and differentiation (D); or components or regulators of the ECM (E). Differences
between groups tested using edgeR: different (q , 0.05) from 0 h IGF1 (a); different (q , 0.05) from 1 h IGF1 (b); different (q,
0.05) from 2 h IGF1 (c); and different (q , 0.05) from 6 h IGF1 (d).
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ERK on the PI3K pathway explains the pronounced
increase in protein synthesis when ERK signaling is
inhibited. Although p-ERKT202/Y204 did not play a role in
IRS1S612 or IRS1Y608 phosphorylation, inhibition of Akt
activation abolished IRS1S612 phosphorylation and in-
creased IRS1Y608 phosphorylation, suggesting that Akt
or a downstream effector molecule acts to negatively
regulate the PI3K pathway at IRS1. Previous stud-
ies have indicated that p70S6KT389 can phosphory-
late several inhibitory serine residues on IRS1 (59),
and we propose that p70S6KT389 is acting in a similar
way to phosphorylate IRS1S612 and provide feedback
Figure 6. Type I collagen production in tenocytes treated with IGF1. Col1a1 (A) and Col1a2 (B) expression in untreated tenocytes
(0 h) or in tenocytes treated with IGF1 for 1, 2, 6, or 24 h, measured with qPCR. Values are means 6 CV. Differences between
groups tested using a 1-way ANOVA found no significant differences. C) Representative immunocytochemistry of cultured
tenocytes treated with 0 or 100 ng/ml of IGF1 for 24 h. b-tubulin, green; EdU, red; Procol Ia1, magenta. Scale bar, 50 mm in all
images. D) Representative Western blot for procollagen type Ia1 (Procol Ia1) in untreated tenocytes (0 h) or tenocytes treated
with 100 ng/ml of IGF1 for 6 or 24 h. E) Representative Western blot for Procol Ia1 in tenocytes treated with 0, 10, or 100 ng/ml
of IGF1 for 24 h.
Figure 5. Proliferation in tenocytes treated with IGF1. A) Mki67 expression in untreated tenocytes (0 h) or in tenocytes treated
with IGF1 for 1, 2, 6, or 24 h, measured with qPCR. Differences between groups tested using a 1-way ANOVA: different (P, 0.05)
from 0 h (a); different (P , 0.05) from 1 h (b); different (P , 0.05) from 2 h (c); and different (P , 0.05) from 6 h (d). B) The
abundance of proliferating tenocytes (expressed as a percentage of total tenocytes) and Mki67 expression (C) in untreated cells
or in cells treated with IGF1, IGF1 and wortmannin, or IGF1 and PD98059 for 2 h. Inset (B) is a representative image
demonstrating BrdU+ nuclei (red) and total nuclei (blue). Scale bar, 30 mm. Differences tested with a 1-way ANOVA: significantly
different (P , 0.05) from control (a); significantly different (P , 0.05) from IGF1 (b); and significantly different (P , 0.05) from
IGF1 and wortmannin (c). Values are means 6 CV; n $ 4 replicates/group.
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inhibition on IGF1-mediated PI3K/Akt activation in
tenocytes. Combined, these results indicate that the
PI3K/Akt and ERK pathways interact downstream
of IGF1 to control tenocyte proliferation and protein
synthesis.
There are several limitations to this study. We only in-
cluded male mice, and additional experiments evaluating
the roleof sexwill likelyprovide further insight into the role
of IGF1 in tendon adaptation. The plantaris overload syn-
ergist ablation technique used in this study is a supra-
physiological growth stimulus that exceeds the normal
growth signals tendons experience with exercise training.
We only evaluated through 2 wk after mechanical over-
load, and it is likely that IGF1 continues to have an in-
fluence on neotendon matrix growth and maturation
beyond this point. Tendonmechanical propertieswere not
assessed in this study, which limits interpretations about
functional changes in mechanically overloaded tendons.
We did not measure cell proliferation in nonoverloaded
mice in this study, but we and others have previously
shown very low proliferation rates of tenocytes in tendons
of adultmice and rats at this age (6, 22, 60).We focused our
analysis on the PI3K/Akt and ERKpathways based on the
bioinformatics results, but it is likely IGF1 also regulates
other downstream pathways in tenocytes. IGF1R was not
completely abolished in tendons because cells other than
tenocytes may also express this receptor. Despite these
limitations, we feel that this study provided novel insight
into the role of IGF1 signaling in regulating tendongrowth.
The ability of tendon to grow and respond to mechan-
ical and biochemical cues requires the coordination of
multiple biologic processes. Studies of 3-dimensional tis-
sue engineered tendon constructs in culture and exercise
training in human subjects have shown that tendons grow
best in response to intermittent mechanical loading with
adequate rest periods built in between loading regimes
(3–5,61,62).Failureof tendons to respond to these cues can
lead to the development of tendinopathies or tendon
ruptures (8). The results in the current study demonstrate
an important role for IGF1 signaling in the growth of
tendons in adult animals andprovidemechanistic support
for the potential use of IGF1 in the treatment of tendino-
pathies. This is further supported by results from a small
Figure 7. Protein synthesis in tenocytes treated with IGF1. Representative Western blot for proteins that have incorporated
puromycin (A) and quantification of band densitometry for tenocytes (B) that were untreated or were treated with IGF1, IGF1
and cycloheximide, IGF1 and wortmannin, or IGF1 and PD98059. C) Representative Western blots for p-ERK1/2T202/Y204, total
ERK1/2, p-ELKS383, total ELK, IRS1Y608, IRS1S612, total IRS1, p-AktT308, and total Akt in untreated cells or in cells treated with
IGF1, IGF1 and wortmannin, or IGF1 and PD98059. Differences tested with a 1-way ANOVA: significantly different (P , 0.05)
from 2IGF1 controls. Coomassie stained membranes are shown as total protein loading controls. Values are means 6 CV; n $ 4
replicates/group.
Figure 8. IGF1 signaling in tenocytes. Diagram of the proposed
regulation of tenocyte proliferation and protein synthesis by
IGF1.
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trial that demonstrated IGF1 increased collagen content
andcell proliferation inhorseswith tendinopathy (14), and
local injection of IGF1 into the tendons of elderly men in-
creased local collagen production (13). However, it is un-
likely that the use of growth factors alone would be
sufficient to treat tendon disorders. High-load eccentric
resistance training can reduce pain and improve ECM
structural organization in patients with tendinopathy, al-
though this training does not lead to full symptomatic
resolution for many patients (63, 64). Recent studies have
demonstrated that tendons synthesizecollagenduringrest
phases at night and assemble collagen into mature fibrils
during the activedayphases (65, 66).Combining theuse of
recombinant growth factors with properly timed me-
chanical loading interventions and appropriate rest pe-
riods could lead to the improved treatment of tendon
disorders. Although IGF1 appears to be a critical pathway
in modulating tendon growth, further studies that in-
tegrate molecular genetics, cell biology, and mechano-
transduction will provide additional insight into the basic
mechanisms of tendon growth and likely lead to the de-
velopment of novel biomarkers of early tendinopathic
changes and improved treatments of painful and de-
bilitating tendon disorders.
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